Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Receives $38.00 Average Target Price from Analysts

Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) has received a consensus recommendation of “Buy” from the five ratings firms that are covering the stock, MarketBeat Ratings reports. Five equities research analysts have rated the stock with a buy recommendation. The average twelve-month price target among brokers that have covered the stock in the last year is $38.80.

KNSA has been the topic of several research analyst reports. Jefferies Financial Group raised their price target on shares of Kiniksa Pharmaceuticals from $40.00 to $45.00 and gave the stock a “buy” rating in a research report on Tuesday, April 29th. Citigroup assumed coverage on Kiniksa Pharmaceuticals in a report on Thursday, March 13th. They issued a “buy” rating and a $40.00 price target for the company. Finally, Wedbush reissued an “outperform” rating and set a $34.00 price objective on shares of Kiniksa Pharmaceuticals in a report on Wednesday, April 16th.

Kiniksa Pharmaceuticals Price Performance

KNSA stock opened at $26.72 on Friday. The stock has a market capitalization of $1.94 billion, a price-to-earnings ratio of -190.84 and a beta of 0.07. The company has a 50-day moving average of $22.31 and a two-hundred day moving average of $21.38. Kiniksa Pharmaceuticals has a 52-week low of $17.38 and a 52-week high of $28.56.

Kiniksa Pharmaceuticals (NASDAQ:KNSA) last released its earnings results on Tuesday, April 29th. The company reported $0.11 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.02 by $0.09. Kiniksa Pharmaceuticals had a negative return on equity of 7.31% and a negative net margin of 2.36%. The firm had revenue of $137.79 million for the quarter, compared to analyst estimates of $128.35 million. During the same quarter last year, the firm posted ($0.25) EPS. The company’s revenue was up 72.5% on a year-over-year basis. Equities analysts expect that Kiniksa Pharmaceuticals will post -0.55 EPS for the current fiscal year.

Insider Transactions at Kiniksa Pharmaceuticals

In other Kiniksa Pharmaceuticals news, COO Eben Tessari sold 14,000 shares of the stock in a transaction on Monday, February 10th. The stock was sold at an average price of $19.57, for a total transaction of $273,980.00. Following the completion of the transaction, the chief operating officer now directly owns 81,975 shares in the company, valued at $1,604,250.75. This represents a 14.59 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Ross Moat sold 18,259 shares of the business’s stock in a transaction on Monday, April 21st. The shares were sold at an average price of $20.29, for a total transaction of $370,475.11. Following the completion of the sale, the insider now owns 9,415 shares in the company, valued at $191,030.35. This represents a 65.98 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 224,820 shares of company stock valued at $5,386,361. Corporate insiders own 54.57% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the company. US Bancorp DE bought a new stake in Kiniksa Pharmaceuticals during the 1st quarter worth approximately $33,000. Wealthquest Corp acquired a new stake in shares of Kiniksa Pharmaceuticals in the first quarter valued at $42,000. Sound View Wealth Advisors Group LLC raised its holdings in shares of Kiniksa Pharmaceuticals by 4.0% in the first quarter. Sound View Wealth Advisors Group LLC now owns 14,657 shares of the company’s stock valued at $326,000 after buying an additional 568 shares during the last quarter. Knights of Columbus Asset Advisors LLC lifted its position in Kiniksa Pharmaceuticals by 2.7% during the 1st quarter. Knights of Columbus Asset Advisors LLC now owns 62,624 shares of the company’s stock worth $1,391,000 after buying an additional 1,658 shares in the last quarter. Finally, Victory Capital Management Inc. bought a new stake in Kiniksa Pharmaceuticals during the 1st quarter worth about $1,184,000. Institutional investors own 53.95% of the company’s stock.

Kiniksa Pharmaceuticals Company Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.